Drug Development Collaboratory (UG3/UH3 Clinical Trial Required)
ArchivedNational Institutes of Health
Description
The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations on late-stage translational science projects between NCATS Therapeutic Development Branch (TDB) and extramural researchers, for therapeutic development of small molecules, biologics, or gene therapies. The UG3 phase will provide support for late stage pre-clinical work and clinical trial planning that is conducted at applicant institutions. The goal of any collaboration with TDB is to enable an IND application by the end of the UG3 phase. If UG3 milestones are met and an IND is cleared, support may be provided for an early stage clinical trials in the UH3 phase that will be conducted at the applicant institutions.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Contact
NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV
- PostedSep 18, 2020
- ClosesJun 9, 2023
- CFDA93.350
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro